ReviewJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2026
Green-synthesized Nanoparticles as Emerging Antidepressant and Anxiolytic Candidates: A Critical Review of Preclinical Evidence and Translational Prospects.
Review in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The high incidence of depression and anxiety disorders worldwide, with figures of depression > 300 million and anxiety > 264 million, poses a serious challenge to health and wellness. Treatment is still limited by existing pharmacotherapies with delayed onset, adverse side effects, poor entry into the blood-brain barrier (BBB), and resistance in approximately 30% of patients. Green-synthesized nanoparticles (NPs) obtained via phytochemicals, microorganisms, and biomolecules are a promising sustainable route for neurotherapeutic applications. This critical review explores preclinical studies on the antidepressant and anxiolytic effects of green NPs, discussing their underlying mechanisms, translatability, and safety concerns in the context of the period 2015-2025. A comprehensive literature search on green synthesis, nanoparticles, Depression, Anxiety and Neurobehavioral outcomes was conducted using the Boolean operator in PubMed, Scopus, Web of Science, and Google Scholar. Evidence suggests that green NPs can facilitate both serotonergic and dopaminergic signal modulation, minimize neuroinflammation, recruit NFκB, activate antioxidant activity via the Nrf2/ HO-1 axis and induce neuroplasticity (Akt/CREB/BDNF axis). Their biogenic characteristics on the surface may enhance BBB transport and biocompatibility and reduce cytotoxicity and environmental persistence. However, there is still inadequate evidence regarding chronic toxicity, biodistribution, synthesis reproducibility, mechanistic validation and clinical evidence. Nano optimization by AI (as well as characterizing nanomaterials in a standardized manner), nanoinformatics and personalized nano-neuropharmacology in the future are required. Green NPs have promising therapeutic potential; however, this has mainly been demonstrated in preclinical studies.
Indexed as
Identifiers
42895587What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.